Table 2.

Results of in vivo efficacy testing of PR-104 treatment at 200 mg/kg once a week for 2 weeks in T-ALL and BCP-ALL xenografts

	Subtype	Treatment	EFS, d	LGD, d	Median ORM	Overall response
ALL-2	BCP-ALL	Vehicle	15.4
		PR-104	31.5	16.1	8	CR
ALL-4	BCP-ALL	Vehicle	5.3
		PR-104	27	21.7	8	CR
ALL-19	BCP-ALL	Vehicle	7.9
		PR-104	18.2	10.3	2	PD2
ALL-8	T-ALL	Vehicle	2.5
		PR-104	56.8	54.3	10	MCR
ALL-27	T-ALL	Vehicle	10.3
		PR-104	69.5	59.2	10	MCR
ALL-29	T-ALL	Vehicle	7.0
		PR-104	51.2	44.2	8	CR
ALL-31	T-ALL	Vehicle	7.0
		PR-104	51.4	44.4	8	CR

P < 0.001 for the LGD of all xenografts treated with PR-104 compared with vehicle.

CR, complete response; EFS, event-free survival; MCR, maintained complete response; PD2, progressive disease 2.